Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Apic Bio, a spin-off from the University of Massachusetts Medical School, has raised $40 million in series A financing to develop gene therapies for people with the neurodegenerative disease amyotrophic lateral sclerosis (ALS) and a rare genetic disease called α-1 antitrypsin deficiency. Apic’s approach, developed at UMass, uses adeno-associated viruses to introduce a microRNA, which silences the mutant gene, along with instructions for a new, functional gene. Apic CEO John Reilly says the funds should get the programs through Phase II clinical studies.
This article has been sent to the following recipient: